On July 13, 2022 Orion Corporation reported that upgrades the full-year outlook for 2022, provided on 10 February 2022, both for the part regarding net sales and operating profit (Press release, Orion , JUL 13, 2022, View Source [SID1234616651]). Due to the collaboration agreement regarding ODM-208, announced at the same time with this release in a separate stock exchange release, and related significant upfront payment, Orion estimates net sales in 2022 to be clearly higher than in 2021. Operating profit is estimated to be clearly higher than in 2021. The upfront payment is USD 290 million of which approximately EUR 220 million is recognised in Orion’s 2022 net sales and operating profit.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

New full-year outlook, provided on 13 July 2022

Orion estimates that net sales in 2022 will be clearly higher than in 2021
(net sales in 2021 were EUR 1,041 million).

Operating profit is estimated to be clearly higher than in 2021.
(operating profit in 2021 was EUR 243 million).

Previous full-year outlook, provided on 10 February 2022

Orion estimates that net sales in 2022 will be at a similar level as in 2021
(net sales in 2021 were EUR 1,041 million).

Operating profit is estimated to be at a similar level as in 2021
(operating profit in 2021 was EUR 243 million).